Intratumoural heterogeneity informs intertumoural heterogeneity. (Upper left) The presence of cytotoxic and effector immune cells leads to better immune responses against glioblastoma. In contrast, the abundance of tumour-associated immune cells leads to immunosuppression and increased gliomagenesis. (Upper right) Release of NLGN3 by neurons and glutamate and dopamine in the neuron-tumour synapses leads to calcium influx into the glioma cell, activating signalling pathways that promote glioma progression and invasiveness. Glioma cells can release TSP-1 that enhances neuronal–tumoural interactions and enforces pro-tumoural signalling. Influx of Cl− through GABAergic channels into the glioma cell inhibits progression. (Bottom) In well perfused tumour parts, oxygenation promotes HIF1A degradation. As the glioma proliferates, it outgrows its vascularization and releases pro-coagulation factors that lead to microvascular thrombosis. This causes hypoxia and the release of HIF1A, which triggers angiogenesis and increases tumoural perfusion. Tumour cells in perinecrotic areas invade areas with better perfusion, increasing invasiveness of glioma and decreasing survival. NKT1 (natural killer T cell type 1), M1 (type 1 macrophage), N1 (neutrophil type 1), DC (dendritic cell), Th1 (type 1 T helper cell), NK1 (natural killer cell type 1), N2 (neutrophil type 2), Treg (regulatory T cell), M2 (type 2 macrophage), MDSC (myeloid-derived suppressor cell), Th2 (type 2 T helper cell), NK2 (natural killer cell type 2), VHL (Von Hippel-Lindau) and VEGF (vascular endothelial growth factor)